Company description

CDNA, or CareDx Inc., is a molecular diagnostics company that specializes in providing innovative solutions for transplant patient monitoring and management. Founded in 1998, CDNA has become a leader in the transplant industry by utilizing the latest advancements in gene expression and transplant science. Their mission is to improve the transplant patient's quality of life by developing and delivering precise and timely information to transplant healthcare providers. CDNA's flagship product, AlloSure, is a non-invasive blood test that monitors gene expression in transplant patients, providing clinicians with important data to help personalize patient care. In addition to AlloSure, CDNA also offers a variety of other products and services, such as AlloMap, AlloSeq, and Olerup SSP, to support transplant patient care. With a strong focus on research and development, CDNA is continually expanding its product offerings and making advancements in the transplant field. The company is committed to improving the lives of transplant patients and their families, and their dedication to innovation has cemented them as a leader in the transplant industry. Currently listed on the NASDAQ under the ticker symbol CDNA, the company continues to grow and make significant contributions to the world of transplant medicine.